Developer docs
API playgroundTry for free, no card

Search company profiles

Quotient Biodiagnostics

Full company profile

uuid0005f1v

Namestring
Quotient Biodiagnostics
Legal namestring
Quotient Limited
Websiteurl
quotientbd.com
Company typeenum
Public
Founded yearint
1992
Descriptiontext

AliveDx (formerly Quotient Biodiagnostics) is a publicly traded in-vitro diagnostics (IVD) company that develops, manufactures, and commercializes products for clinical laboratories and healthcare facilities. The company operates three core product brands: MosaiQ, a microarray-based diagnostic platform designed for multiplexed autoimmune and allergy testing; LumiQ, an all-in-one immunofluorescence (IFA) system intended to pair with MosaiQ as a turnkey autoimmune workflow solution; and Alba, a manual reagent product line serving both clinical laboratories and OEM partners. The company reports over 30 years of experience in immunohematology and in-vitro diagnostics, and its legal entity, Quotient Limited, was incorporated in 1992 and listed on NASDAQ in 2017.

The MosaiQ platform is the company's flagship technology and centers on a proprietary microarray architecture that allows multiple tests to be run simultaneously on a single device, with the stated goal of reducing time-to-diagnosis across autoimmune and allergy indications. The MosaiQ menu includes the AiPlex CTDplus (connective tissue disease), AiPlex CD (celiac disease), AiPlex APS (antiphospholipid syndrome), AiPlex VAS (vasculitis), and AllergyPlex assays. MosaiQ and LumiQ together are positioned as an integrated sample-to-result workflow, while Alba functions as a lower-throughput, complementary manual reagent business with distinct pH-change reactions and room-temperature storage.

AliveDx distributes its products through direct sales to clinical laboratories worldwide and through an OEM channel for Alba reagents. The company employs a horizontal segmentation approach targeting clinical labs broadly across autoimmune, allergy, and related clinical fields, and uses a mix of scientific content marketing, industry conference participation (notably ADLM), and direct consultation request forms as primary commercial channels. Quotient Limited rebranded to AliveDx as its commercial identity in 2023 while retaining the legal entity structure and NASDAQ listing under ticker QUOT.

Short descriptiontext

AliveDx (formerly Quotient Biodiagnostics) develops and manufactures in-vitro diagnostic products for autoimmune and allergy testing, serving clinical laboratories globally through its MosaiQ microarray platform, LumiQ immunofluorescence system, and Alba reagent line.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNewtown, United States
HQ citystring
Newtown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
in-vitro diagnostics, microarray immunoassays, immunohematology reagents, autoimmune disease testing, clinical laboratory solutions
Industry3 codes
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-Vitro Diagnostics
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MosaiQ
Description

Automated microarray immunoassay platform for rapid in-vitro diagnostic testing in autoimmune diseases, allergy, and related clinical fields. Designed to shorten time-to-diagnosis with multiple tests on a single platform.

alivedx.com
+2 more records
Core offering1 text field

Quotient Biodiagnostics (commercially AliveDx) develops and manufactures in-vitro diagnostic products for clinical laboratories. Its portfolio centers on the MosaiQ microarray platform for multiplexed autoimmune, allergy, connective tissue, vasculitis, and celiac disease testing, the LumiQ all-in-one immunofluorescence (IFA) solution, and the Alba manual reagent product line for immunohematology and blood banking workflows.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

AliveDx (formerly Quotient Biodiagnostics/Quotient Limited) offers a portfolio of in-vitro diagnostic solutions designed to promote lab productivity and deliver economic and clinical value for faster disease detection and diagnosis. The product portfolio centers on three main brands: MosaiQ (a microarray diagnostic platform for autoimmune diseases, allergy, and beyond), LumiQ (an all-in-one immunofluorescence IFA solution that complements MosaiQ), and Alba (a manual reagent product line with technical support). With over 30 years of experience in immunohematology and in-vitro diagnostics, the company addresses clinical and laboratory challenges in autoimmune, allergy, and related clinical fields worldwide.

Product and service8 records
1MosaiQ
CategoryDiagnostic platform
Description

A microarray-based in-vitro diagnostic platform designed to shorten time-to-diagnosis for patients by providing faster test results. The single solution performs multiple tests and provides maximum flexibility to laboratorians and clinicians, focusing on autoimmune diseases, allergy, and clinical diagnostics.

2LumiQ
CategoryDiagnostic instrument
Description

An all-in-one Immunofluorescence (IFA) solution designed to provide workflow efficiency from patient sample in to result out. When combined with MosaiQ, it serves as a turnkey automated autoimmune solution.

3Alba
CategoryManual reagent product line
Description

A manual reagent product line backed by expert technical support and reliable customer service. Includes elution kits, OEM solutions, and various reagent products for clinical laboratory use, with features such as distinct pH change reactions and room temperature storage.

4AiPlex CTDplus Assay
CategoryAssay/test kit
Description

An assay designed for use with the MosaiQ microarray platform, targeting connective tissue diseases via multiplexed testing.

5AiPlex CD Assay
CategoryAssay/test kit
Description

An assay for celiac disease diagnostics on the MosaiQ microarray platform.

6AiPlex APS Assay
CategoryAssay/test kit
Description

An assay for antiphospholipid syndrome testing on the MosaiQ microarray platform.

7AiPlex VAS Assay
CategoryAssay/test kit
Description

An assay for vasculitis diagnosis on the MosaiQ microarray platform, detecting ANCA-associated vasculitis markers via multiplexed testing.

8AllergyPlex Assay
CategoryAssay/test kit
Description

An allergy testing assay for the MosaiQ microarray platform, enabling multiplexed allergy diagnostics on a single solution.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specializes in autoimmune disease diagnostics including IFA and multiplex platforms (e.g., BIO-FLASH, Aptiva), directly overlapping AliveDx's MosaiQ and LumiQ franchises across connective tissue disease, vasculitis and celiac testing.

TypeDirect peer
Description

Global autoimmune diagnostics vendor offering IFA, ELISA and microarray/multi-parameter testing; competes head-to-head with AliveDx in autoimmune labs and shares the microarray + IFA integration theme.

TypeBroad incumbent
Description

Diversified life science and clinical diagnostics company with a significant autoimmune and immunohematology portfolio (e.g., BioPlex 2200) that competes with MosaiQ's multiplex positioning while offering broader menu and global reach.

TypeDirect peer
Description

Public IVD company developing autoimmune, infectious disease and hemoglobin diagnostics; comparable in scale, public-market profile and autoimmune focus, making it a near-direct investment comparable for AliveDx.

5Abbott Diagnostics
TypeBroad incumbent
Description

Major diagnostics incumbent with extensive autoimmune, allergy and immunohematology menus on ARCHITECT and Alinity platforms; competes on workflow consolidation, scale and global lab relationships.

TypeBroad incumbent
Description

World-leading IVD provider (cobas, Elecsys) covering autoimmune, allergy and immunohematology; represents the scale and menu breadth benchmark that AliveDx must differentiate against.

TypeBroad incumbent
Description

Operates the Phadia/ImmunoCAP allergy platform, directly overlapping AliveDx's AllergyPlex offering, while also supplying a broad IVD and life sciences portfolio to clinical labs.

TypeBroad incumbent
Description

Major IVD incumbent (ADVIA Centaur, Atellica) with autoimmune and allergy assays; comparable as a competing integrated platform vendor targeting high-volume reference labs.

TypeEmerging player
Description

Specialized autoimmune diagnostics vendor offering IFA and ELISA assays; comparable in niche focus to AliveDx but smaller scale and more limited menu.

10ImmunoConcepts
TypeEmerging player
Description

Autoimmune diagnostics company focused on IFA reagents and instrumentation for connective tissue disease and infectious disease serology; an adjacent niche player with overlapping customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quotient Biodiagnostics

In-Vitro Diagnosticsquotientbd.com

AliveDx (formerly Quotient Biodiagnostics) develops and manufactures in-vitro diagnostic products for autoimmune and allergy testing, serving clinical laboratories globally through its MosaiQ microarray platform, LumiQ immunofluorescence system, and Alba reagent line.

What Quotient Biodiagnostics does

AliveDx (formerly Quotient Biodiagnostics) is a publicly traded in-vitro diagnostics (IVD) company that develops, manufactures, and commercializes products for clinical laboratories and healthcare facilities. The company operates three core product brands: MosaiQ, a microarray-based diagnostic platform designed for multiplexed autoimmune and allergy testing; LumiQ, an all-in-one immunofluorescence (IFA) system intended to pair with MosaiQ as a turnkey autoimmune workflow solution; and Alba, a manual reagent product line serving both clinical laboratories and OEM partners. The company reports over 30 years of experience in immunohematology and in-vitro diagnostics, and its legal entity, Quotient Limited, was incorporated in 1992 and listed on NASDAQ in 2017.

The MosaiQ platform is the company's flagship technology and centers on a proprietary microarray architecture that allows multiple tests to be run simultaneously on a single device, with the stated goal of reducing time-to-diagnosis across autoimmune and allergy indications. The MosaiQ menu includes the AiPlex CTDplus (connective tissue disease), AiPlex CD (celiac disease), AiPlex APS (antiphospholipid syndrome), AiPlex VAS (vasculitis), and AllergyPlex assays. MosaiQ and LumiQ together are positioned as an integrated sample-to-result workflow, while Alba functions as a lower-throughput, complementary manual reagent business with distinct pH-change reactions and room-temperature storage.

AliveDx distributes its products through direct sales to clinical laboratories worldwide and through an OEM channel for Alba reagents. The company employs a horizontal segmentation approach targeting clinical labs broadly across autoimmune, allergy, and related clinical fields, and uses a mix of scientific content marketing, industry conference participation (notably ADLM), and direct consultation request forms as primary commercial channels. Quotient Limited rebranded to AliveDx as its commercial identity in 2023 while retaining the legal entity structure and NASDAQ listing under ticker QUOT.

Quotient Biodiagnostics firmographics

Firmographics
Name
Quotient Biodiagnostics
Legal name
Quotient Limited
Website
https://quotientbd.com
Company type
Public
Founded year
1992
Operating status
Operating
Headcount range
251–500 employees
Short description
AliveDx (formerly Quotient Biodiagnostics) develops and manufactures in-vitro diagnostic products for autoimmune and allergy testing, serving clinical laboratories globally through its MosaiQ microarray platform, LumiQ immunofluorescence system, and Alba reagent line.
Ownership category
akta.pro rank

Quotient Biodiagnostics industry classification

Industry
Product category
In-Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAK
Autoimmune, Allergy & Specialized Immunology Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • In-vitro diagnostics
  • Microarray immunoassays
  • Immunohematology reagents
  • Autoimmune disease testing
  • Clinical laboratory solutions

Where Quotient Biodiagnostics is headquartered

Location

Headquarters

HQ city
Newtown
HQ country
United States
HQ region
North America

Markets served

Quotient Biodiagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Distribution channels2 records

Marketing channels4 records

Quotient Biodiagnostics product offering

Product offering

Core offering

Quotient Biodiagnostics (commercially AliveDx) develops and manufactures in-vitro diagnostic products for clinical laboratories. Its portfolio centers on the MosaiQ microarray platform for multiplexed autoimmune, allergy, connective tissue, vasculitis, and celiac disease testing, the LumiQ all-in-one immunofluorescence (IFA) solution, and the Alba manual reagent product line for immunohematology and blood banking workflows.

Product overview

AliveDx (formerly Quotient Biodiagnostics/Quotient Limited) offers a portfolio of in-vitro diagnostic solutions designed to promote lab productivity and deliver economic and clinical value for faster disease detection and diagnosis. The product portfolio centers on three main brands: MosaiQ (a microarray diagnostic platform for autoimmune diseases, allergy, and beyond), LumiQ (an all-in-one immunofluorescence IFA solution that complements MosaiQ), and Alba (a manual reagent product line with technical support). With over 30 years of experience in immunohematology and in-vitro diagnostics, the company addresses clinical and laboratory challenges in autoimmune, allergy, and related clinical fields worldwide.

Differentiator

Problem solved

Functional benefit

Brands

  • MosaiQ: Automated microarray immunoassay platform for rapid in-vitro diagnostic testing in autoimmune diseases, allergy, and related clinical fields. Designed to shorten time-to-diagnosis with multiple tests on a single platform.
  • LumiQ
  • Alba

Products and services

  • MosaiQ A microarray-based in-vitro diagnostic platform designed to shorten time-to-diagnosis for patients by providing faster test results. The single solution performs multiple tests and provides maximum flexibility to laboratorians and clinicians, focusing on autoimmune diseases, allergy, and clinical diagnostics.
  • LumiQ An all-in-one Immunofluorescence (IFA) solution designed to provide workflow efficiency from patient sample in to result out. When combined with MosaiQ, it serves as a turnkey automated autoimmune solution.
  • Alba A manual reagent product line backed by expert technical support and reliable customer service. Includes elution kits, OEM solutions, and various reagent products for clinical laboratory use, with features such as distinct pH change reactions and room temperature storage.
  • AiPlex CTDplus Assay An assay designed for use with the MosaiQ microarray platform, targeting connective tissue diseases via multiplexed testing.
  • AiPlex CD Assay An assay for celiac disease diagnostics on the MosaiQ microarray platform.
  • AiPlex APS Assay An assay for antiphospholipid syndrome testing on the MosaiQ microarray platform.
  • AiPlex VAS Assay An assay for vasculitis diagnosis on the MosaiQ microarray platform, detecting ANCA-associated vasculitis markers via multiplexed testing.
  • AllergyPlex Assay An allergy testing assay for the MosaiQ microarray platform, enabling multiplexed allergy diagnostics on a single solution.

Companies that use Quotient Biodiagnostics

Customer profile

Segments1 record

Ideal customer profiles1 record

Quotient Biodiagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Quotient Biodiagnostics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Quotient Biodiagnostics competitors and assessment

Company assessment

Direct peers

  • Werfen (Inova Diagnostics): Specializes in autoimmune disease diagnostics including IFA and multiplex platforms (e.g., BIO-FLASH, Aptiva), directly overlapping AliveDx's MosaiQ and LumiQ franchises across connective tissue disease, vasculitis and celiac testing.
  • Euroimmun (PerkinElmer): Global autoimmune diagnostics vendor offering IFA, ELISA and microarray/multi-parameter testing; competes head-to-head with AliveDx in autoimmune labs and shares the microarray + IFA integration theme.
  • Trinity Biotech: Public IVD company developing autoimmune, infectious disease and hemoglobin diagnostics; comparable in scale, public-market profile and autoimmune focus, making it a near-direct investment comparable for AliveDx.

Broad incumbents

  • Bio-Rad Laboratories: Diversified life science and clinical diagnostics company with a significant autoimmune and immunohematology portfolio (e.g., BioPlex 2200) that competes with MosaiQ's multiplex positioning while offering broader menu and global reach.
  • Abbott Diagnostics: Major diagnostics incumbent with extensive autoimmune, allergy and immunohematology menus on ARCHITECT and Alinity platforms; competes on workflow consolidation, scale and global lab relationships.
  • Roche Diagnostics: World-leading IVD provider (cobas, Elecsys) covering autoimmune, allergy and immunohematology; represents the scale and menu breadth benchmark that AliveDx must differentiate against.
  • Thermo Fisher Scientific (Phadia/ImmunoCAP): Operates the Phadia/ImmunoCAP allergy platform, directly overlapping AliveDx's AllergyPlex offering, while also supplying a broad IVD and life sciences portfolio to clinical labs.
  • Siemens Healthineers: Major IVD incumbent (ADVIA Centaur, Atellica) with autoimmune and allergy assays; comparable as a competing integrated platform vendor targeting high-volume reference labs.

Emerging players

  • Aesku.Diagnostics: Specialized autoimmune diagnostics vendor offering IFA and ELISA assays; comparable in niche focus to AliveDx but smaller scale and more limited menu.
  • ImmunoConcepts: Autoimmune diagnostics company focused on IFA reagents and instrumentation for connective tissue disease and infectious disease serology; an adjacent niche player with overlapping customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Quotient Biodiagnostics social profiles

Digital presence

Quotient Biodiagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quotient Biodiagnostics leadership team

Management profile

Number of profiles

Profiles6 records

Quotient Biodiagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Quotient Biodiagnostics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quotient Biodiagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quotient Biodiagnostics

What does Quotient Biodiagnostics do?

Quotient Biodiagnostics (commercially AliveDx) develops and manufactures in-vitro diagnostic products for clinical laboratories. Its portfolio centers on the MosaiQ microarray platform for multiplexed autoimmune, allergy, connective tissue, vasculitis, and celiac disease testing, the LumiQ all-in-one immunofluorescence (IFA) solution, and the Alba manual reagent product line for immunohematology and blood banking workflows.

Is Quotient Biodiagnostics a public or private company?

Quotient Biodiagnostics is a public company. It is classified as public and is currently operating.

When was Quotient Biodiagnostics founded?

Quotient Biodiagnostics was founded in 1992. It employs 251 to 500 people.

Where is Quotient Biodiagnostics based?

Quotient Biodiagnostics is headquartered in Newtown, United States, in the North America region.

Who are Quotient Biodiagnostics's main competitors?

Direct peers on record are Werfen (Inova Diagnostics), Euroimmun (PerkinElmer) and Trinity Biotech. Broad incumbents are Bio-Rad Laboratories, Abbott Diagnostics, Roche Diagnostics, Thermo Fisher Scientific (Phadia/ImmunoCAP) and Siemens Healthineers. Emerging players are Aesku.Diagnostics and ImmunoConcepts.

Does Quotient Biodiagnostics have an API?

No public API is recorded for Quotient Biodiagnostics.

What industry is Quotient Biodiagnostics in?

Quotient Biodiagnostics's product category is In-Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAK, Autoimmune, Allergy & Specialized Immunology Diagnostics, with a secondary code of HLAAALAK, Autoimmune & Allergy Diagnostics. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireQuotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global MarketQuotient Limited announced its intent to voluntarily delist from Nasdaq, filing Form 25 on December 27, 2022. The delisting will take effect no earlier than ten days after filing, with the last trading day expected on January 6, 2023. The company does not plan to list on any other exchange.GlobeNewswireQuotient Limited Announces Reverse Stock Split Effective TodayQuotient Limited announced a 1-for-40 reverse stock split effective today, with shares trading on a split-adjusted basis on November 3, 2022. The split aims to meet Nasdaq's minimum bid price requirement, and shareholders will receive cash for fractional shares.GlobeNewswireQuotient Limited Announces Intent to Effect Reverse Stock SplitQuotient Limited announced a one-for-40 reverse stock split effective November 2, 2022, to meet Nasdaq's minimum bid price requirement. The split reduces outstanding shares from about 141.2 million to 3.53 million, with fractional shares paid in cash.GlobeNewswireQuotient Limited Selected to Join the World Economic Forum New Champions CommunityQuotient Limited was selected by the World Economic Forum to join its New Champions Community. The company's MosaiQ solution, a multiplex microarray platform, aims to increase laboratory efficiencies and transform patient care. Quotient's CEO said the partnership will help build a better future through innovation in blood security and diagnostics.GlobeNewswireQuotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory EfficienciesQuotient Limited announced that Sanquin Blood Supply Foundation has joined its MosaiQ Innovator's Circle. The partnership aims to improve patient care and laboratory efficiencies through innovation in transfusion medicine. Quotient's MosaiQ solution is a multiplex microarray platform for automated testing.GlobeNewswireQuotient Limited Provides First Quarter Fiscal 2023 Results and Business UpdateQuotient Limited reported Q1 FY2023 revenue of $8.8 million and $63.2 million in cash and investments as of June 30, 2022. The company also signed ten distribution agreements and expects its Extended Serological Disease Screening microarray to launch in calendar year 2023.GlobeNewswireQuotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9thQuotient Limited will report its first quarter fiscal 2023 financial results before market open on August 9, 2022, and host a conference call with CEO Manuel O. Méndez and CFO Ali J. Kiboro. The company, a commercial-stage diagnostics firm, will also provide a webcast replay.GlobeNewswireQuotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease MenuQuotient Limited and InfYnity Biomarkers announced a partnership to expand Quotient's MosaiQ infectious disease testing menu. InfYnity will assist in research and design of infectious disease assays to enrich the MosaiQ Serology Disease Screening menu and reduce development time and cost. The collaboration aims to accelerate development timelines and access infectious disease screening and clinical diagnostic markets.GlobeNewswireQuotient Limited Announces Equity AwardsQuotient Limited appointed Steven Zuiderwijk as Chief Strategy & Business Development Officer, effective July 1, 2022. The company granted him 112,780 performance-based PSUs, 67,668 RSUs, and options for 45,112 shares, with vesting tied to service and financial targets.GlobeNewswireQuotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded WarrantsQuotient Limited closed an underwritten public offering of 32,458,336 ordinary shares and pre-funded warrants, raising approximately $20.0 million in gross proceeds. Net proceeds of about $18.5 million will fund development and commercialization of its MosaiQ microarray menu and working capital.